INTRODUCTION {#s1}
============

Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have emerged as an important type of anticancer agents. Regorafenib, a novel oral VEGFR TKI, has a distinct molecular target profile and more potent pharmacological activity than sorafenib in pre-clinical investigations \[[@R1]\]. It can inhibit the activity of angiogenic, stromal and oncogenic tyrosine kinases by targeting VEGFR 1, 2 and 3, tyrosine protein kinase receptor Ret, platelet-derived growth factor beta, basic fibroblast growth factor receptor-1, tyrosine-protein kinase TIE-2, proto-oncogene RAF-1, c-KIT, BRAF, and p38 MAP kinase \[[@R1], [@R2]\]. Currently, regorafenib has been approved by the United States Food and Drug Administration (FDA) for the treatment of advanced gastrointestinal stromal tumor (GIST) \[[@R3]\], metastatic colorectal cancer (CRC) \[[@R4]\], and recently, advanced hepatocellular carcinoma (HCC) \[[@R5]\].

Compared with traditional cytotoxic chemotherapeutic agents, VEGF-targeted TKIs, such as regorafenib, sunitinib and sorafenib are associated with a distinct profile of adverse events (AEs) \[[@R6]--[@R8]\]. Previous studies have showed an increased risk of developing hypertension \[[@R9]\], hand-foot skin reaction \[[@R10]\], hematologic toxicities \[[@R11], [@R12]\], and arterial thromboembolism \[[@R13]\] in patients treated with VEGF-TKIs. In addition, the significant risk of hepatic AE associated with TKI has been reported \[[@R14], [@R15]\]. It has shown that the incidence of all-grade hepatotoxicity of TKI ranged from 11% (gefitinib) to over 50% (Pazopanib). As for high-grade hepatic AE, the frequencies vary from 1% to 12% \[[@R14]\].

Liver dysfunction is often associated with various symptoms, accordingly a number of biomarkers for cancer therapy induced hepatotoxicity have been identified in the past several decades. Although albumin concentration and prothrombin time (PT) were often used to assess liver function. However, some conditions like heart failure, nephrosis and chronic inflammatory conditions also cause the hypoalbuminemia which can be present in cancer patients. Similarly, it could be difficult to classify patients who is on warfarin, heparin or direct thrombin inhibitors which prolonged PT. In this study, hepatic adverse effects mainly manifest as asymptomatic increase of bilirubin, aspartate transaminase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP).

Fatal adverse events caused by hepatic failure/dysfunction associated with regorafenib-treatment have been reported in several randomized controlled trials (RCTs) such as GRID \[[@R16]\], INTEGRATE \[[@R17]\] and REGOSARC \[[@R18]\]. In addition, the risk for serious hepatotoxicity with regorafenib is believed to be so high that FDA ordered the inclusion of extra labels, the so-called "black box warnings", to indicate the increased risk of liver injury when patients were treated with regorafenib. However, there has been no systematic attempt to evaluate the overall risk of hepatic toxicities induced by regorafenib. Currently, regorafenib is being investigated in several types of tumors and an increase in the application of regorafenib could be expected in the near future. Accordingly, here we conducted a meta-analysis of available clinical studies to determine the overall incidence and relative risk of developing hepatic AEs in patients treated with regorafenib.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

A total of 946 potentially relevant studies were identified by the initial search strategy, including 465 articles on regorafenib from PubMed and 481 papers on regorafenib from Embase database. 503 studies were removed because of duplications. 424 articles were further excluded because they did not satisfy the inclusion criteria. When carefully reviewed the full texts of the remaining 19 potentially eligible papers, 5 more were not included because of insufficient data (*n* = 2) \[[@R16], [@R18]\], different dose of regorafenib (*n* = 2) \[[@R19], [@R20]\] and duplication (*n* = 1) \[[@R21]\]. A total of 14 trials were selected for the final analysis. 10 studies were single arm trials \[[@R22]--[@R31]\], the other 4 were RCTs \[[@R17], [@R32]--[@R34]\]. A flow chart showing the study selection was presented in Figure [1](#F1){ref-type="fig"}.

![Flow-chart diagram of selected trials included in this meta-analysis](oncotarget-08-84102-g001){#F1}

Study quality {#s2_2}
-------------

All included phase III trials involved randomized treatment allocation \[[@R32]--[@R34]\]. Of the rest 11 trials, 10 trials were single-arm trials \[[@R22]--[@R31]\], INTEGRATE was double-blind RCT. For quality analysis purposes, we calculated the incidence in randomized versus non-randomized trials (phase III versus non-phase III). We found no statistically significant difference between subgroups (Data not shown).

Population characteristics {#s2_3}
--------------------------

A total of 2,213 subjects were included in this meta-analysis (regorafenib: 1,649; control: 564). 1,428 subjects had colorectal cancer (regorafenib: 1,107; control: 321) from 9 trials. 603 patients had hepatocellular carcinoma (regorafenib: 410; control: 193) from 2 trials. 147 subjects had gastric cancer (regorafenib: 97; control: 50) from 1 trial. 20 patients had gastrointestinal stromal tumor (regorafenib: 20; control: 0) from 1 trial. The schedule and dose of regorafenib for all trials were 160 mg once daily orally for the first 21 days of each 28-day cycle, the currently FDA-recommended dose until disease progression or unacceptable toxicity. The median treatment ranged from 1.7 months to 9.3 months. The clinic-pathological characteristics of eligible studies were summarized in Table [1](#T1){ref-type="table"}. The numbers of all-grade and high-grade hepatic AEs for each trial were presented in Table [2](#T2){ref-type="table"}. It was noted that not all trials consistently reported the four hepatic adverse events of our interest.

###### Baseline characteristics of the clinical trials included in this study

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                  Region      Year   Underlying malignancy   Follow-up, median (range), month   No. of patients   Median age (range), year   Gender\         ECOG PS (0/1/2)   Treatment duration, median (range), month   Median OS (95% CI), month   Median PFS (95% CI), month
                                                                                                                                                     (male/female)                                                                                             
  ----------------------- ----------- ------ ----------------------- ---------------------------------- ----------------- -------------------------- --------------- ----------------- ------------------------------------------- --------------------------- ----------------------------
  Li \[[@R32]\]           Asia        2015   CRC                     7.4 (4.3--12.2)                    136\              58 (50--66)\               85/51\          35/101/0\         2.4 (1.6--5.3)\                             8.8 (7.3--9.8)\             3.2 (2.0--3.7)\
                                                                                                        68                56 (49--62)                33/35           15/53/0           1.6 (1.1--1.6)                              6.3 (4.8--7.6)              1.7 (1.6--1.8)

  Grothey \[[@R33]\]      Globe       2013   CRC                     NR                                 500\              61 (54--67)\               311/194\        265/240/0\        1.7 (1.4--3.7)\                             NR\                         1.9 (1.6--3.9)\
                                                                                                        253               61 (54--68)                153/102         146/109/0         1.6 (1.3--1.7)                              NR                          1.7 (1.4--1.9)

  Pavlakis \[[@R17]\]     Globe       2016   GC                      17.1 (14.6--19.4)                  97\               63 (33--81)\               78/19\          41/56/0\          1.8 (1.4--2.0)\                             5.8 (4.4--6.8)\             2.6 (1.8--3.1)\
                                                                                                        50                62 (32--85)                40/10           21/29/0           0.9 (0.9--1.0)                              4.5 (3.4--5.2)              0.9 (0.9--0.9)

  Bruix \[[@R34]\]        Globe       2017   HCC                     7.0 (3.7--12.6)                    379\              64 (54--71)\               333/46\         247/132/0\        3.6 (1.6--7.6)\                             10.6 (9.1--12.1)\           3.1 (2.8--4.2)\
                                                                                                        194               62 (55--68)                171/23          130/64/0          1.9 (1.4--3.9)                              7.8 (6.3--8.8)              1.5 (1.4--1.6)

  Argiles \[[@R22]\]      Globe       2015   CRC                     NR                                 53                61 (32--80)                28/26           35/19/0           7.7 (0.1--19.5)                             NR                          8.5 (7.4--11.3)

  Kollar \[[@R23]\]       UK          2014   GIST                    12.6                               20                68 (45--87)                13/7            18/2\*            9.3 (0.1--15.3)                             12.2                        9.4

  Sueda \[[@R24]\]        Japan       2016   CRC                     5.5                                23                59 (37--83)                12/11           10/13/0           2.3 (0.1--14.7)                             5.8 (3.7--11.7)             3.0 (1.6--4.5)

  Masuishi \[[@R25]\]     Japan       2017   CRC                     6.5                                146               NR                         90/56           135/11\*          NR                                          6.7 (5.8--7.6)              2.1 (1.8--2.5)

  Del Prete \[[@R26]\]    Italy       2017   CRC                     NR                                 136               57 (31--79)                92/44           104/32\*          3.5                                         8.9                         2.8

  Zanwar \[[@R27]\]       India       2016   CRC                     NR                                 23                50                         12/11           2/15/6            3.8                                         NR                          NR

  Bruix \[[@R28]\]        Globe       2013   HCC                     NR                                 36                61 (40--76)                32/4            28/8/0            4.9 (0.5--25.8)                             13.8 (9.3--18.3)            4.3 (2.9--13.1)

  Lam \[[@R29]\]          Hong Kong   2016   CRC                     6.4                                45                63 (45--80)                32/13           41/4\*            3.0 (1.0--16.0)                             7.6 (4.2--11.1)             3.9 (3.3--4.5)

  Schultheis \[[@R30]\]   German      2013   CRC                     NR                                 45                65 (18--80)                27/18           27/16/0           3.6 (0.1--11.5)                             NR                          4.0 (1.5--11.3)

  Sunakawa \[[@R31]\]     Japan       2013   Solid tumor             NR                                 15                59 (34--68)                11/4            12/3/0            2.1 (0.9--20.1)                             NR                          3.7 (1.9--12.4)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CRC, colorectal cancer; GC, gastric cancer; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; PFS, progress-free survival; OS, overall survival. NR, not reported; ECOG PS, European cooperative oncology group performance status; \*, ECOG 0-1/ECOG 2.

###### Number of events reported in every trial included in this study

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                  Year         Underlying malignancy   No. of patients   Events of bilirubin elevation   Events of AST elevation   Events of ALT elevation   Event of ALP elevation   CTCAE                     
  ----------------------- ------------ ----------------------- ----------------- ------------------------------- ------------------------- ------------------------- ------------------------ ------- ----- ----- ----- ------
  All-grade               High-grade   All-grade               High-grade        All-grade                       High-grade                All-grade                 High-grade                                         

  Li \[[@R32]\]           2015         CRC                     136\              50\                             9\                        32\                       8\                       32\     9\    3\    0\    4.0
                                                               68                5                               1                         6                         0                        5       0     1     1     

  Grothey \[[@R33]\]      2013         CRC                     500\              100\                            38\                       35\                       12\                      27\     10\   32\   11\   3.0
                                                               253               24                              16                        10                        3                        5       0     8     4     

  Pavlakis \[[@R17]\]     2016         GC                      97\               NR\                             NR\                       NR\                       9\                       NR\     8\    NR\   NR\   4.0
                                                               50                NR                              NR                        NR                        0                        NR      3     NR    NR    

  Bruix \[[@R34]\]        2017         HCC                     374\              70\                             25\                       48\                       19\                      29\     8\    NR\   NR\   4.03
                                                               193               7                               4                         15                        10                       8       2     NR    NR    

  Argiles \[[@R22]\]      2015         CRC                     53                NR                              NR                        12                        3                        NR      NR    NR    NR    NR

  Kollar \[[@R23]\]       2014         GIST                    20                2                               1                         NR                        NR                       NR      NR    NR    NR    4.0

  Sueda \[[@R24]\]        2016         CRC                     23                8                               1                         NR                        NR                       NR      NR    NR    NR    4.0

  Masuishi \[[@R25]\]     2017         CRC                     146               70                              11                        107                       19                       77      14    NR    NR    4.0

  Del Prete \[[@R26]\]    2017         CRC                     136               5                               0                         5                         3                        NR      NR    NR    NR    4.03

  Zanwar \[[@R27]\]       2016         CRC                     23                4                               1                         NR                        NR                       NR      NR    NR    NR    4.03

  Bruix \[[@R28]\]        2013         HCC                     36                4                               2                         NR                        NR                       NR      NR    NR    NR    3.0

  Lam \[[@R29]\]          2016         CRC                     45                17                              1                         26                        4                        15      3     NR    NR    4.0

  Schultheis \[[@R30]\]   2013         CRC                     45                NR                              NR                        3                         0                        4       2     NR    NR    3.0

  Sunakawa \[[@R31]\]     2013         Solid tumor             15                NR                              NR                        8                         2                        7       2     14    2     3.0
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CTCAE, common terminology criteria for adverse events; AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CRC, colorectal cancer; GC, gastric cancer; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; NR, not reported.

Overall incidence of hepatotoxicity {#s2_4}
-----------------------------------

The pooled incidences of all-grade hepatic toxicities were: increased blood bilirubin, 23% (95% CI, 15%--32%); elevated AST, 32% (95% CI, 19%--46%); elevated ALT, 27% (95% CI, 16%--38%) and elevated ALP, 31% (95% CI, 13%--50%). The incidences of high-grade hepatic AEs were: increased blood bilirubin, 5% (95% CI, 2%--8%); elevated AST, 6% (95% CI, 3%--8%); elevated ALT, 5% (95% CI, 3%--7%) and elevated ALP, 2% (95% CI, 1%--3%). The test for heterogeneities were significant for all-grade and high-grade of these four hepatic AEs (*p* \< 0.05 or I^2^ \> 25%). Accordingly, the random-effects models were used.

Relative risk of hepatic toxicity events {#s2_5}
----------------------------------------

A meta-analysis of the RRs and their 95% CIs of both all-grade and high-grade hepatic toxicities was performed on 4 RCTs (3 phase III studies and 1 phase II studies). A total of 1,671 patients were included, 1,107 of them were treated with regorafenib, the rest 564 subjected were treated with placebo. The RRs and their 95% CIs of all-grade elevation of bilirubin, AST, ALT and ALP were 3.10 (95% CI, 2.22--4.34; *p \<* 0.001), 1.51(95% CI, 1.13--2.00; *p \<* 0.01), 1.82 (95% CI, 1.25--2.64; *p \<* 0.001) and 2.11 (95% CI, 1.01--4.40; *p \<* 0.05), respectively (Figure [2](#F2){ref-type="fig"}). The relative risk of high-grade elevation of bilirubin, AST, ALT and ALP in subjects treated with regorafenib were 1.74 (95% CI, 1.09--2.80; *p \<* 0.01), 1.79 (95% CI, 1.00--3.22; *p \<* 0.05), 3.07 (95% CI, 1.30--7.22; *p \<* 0.01) and 1.06 (95% CI, 0.39--2.90; *p \>* 0.05), respectively (Figure [3](#F3){ref-type="fig"}).

![Forest plots of relative risk (RR) of all-grade hepatic toxicities associated with regorafenib versus control\
The size of squares corresponds to the weight of the trial in the meta-analysis.](oncotarget-08-84102-g002){#F2}

![Forest plots of relative risk (RR) of high-grade hepatic toxicities associated with regorafenib versus control\
The size of squares corresponds to the weight of the trial in the meta-analysis.](oncotarget-08-84102-g003){#F3}

Publication bias {#s2_6}
----------------

We found no evidence of publication bias for RR of both all-grade and high-grade hepatotoxicities by either the Egger or the Begg test (*p* \> 0.05).

DISCUSSION {#s3}
==========

The exact incidence of drug-induced hepatic injury is difficult to investigate as the number of patients using any specific anti-cancer agent is uncertain. There is no easy examination for its diagnosis and systemic reporting is incomplete \[[@R35]\]. To our knowledge, this is the first meta-analysis focusing specifically on hepatic toxicities associated with regorafenib. Our results revealed the incidence of regorafenib-induced all-grade and high-grade (grade 3 and 4) hepatic toxicities were: bilirubin elevation: 23% and 5%; AST elevation: 32% and 6%; ALT elevation: 27% and 5%; ALP elevation: 31% and 2%. Furthermore, our analysis demonstrated the risk of developing all-grade hepatic toxicities was approximately two-fold higher in patients treated by regorafenib compared to patients in the placebo or controlled arms. High-grade bilirubin, AST and ALT elevations also significantly increased, while high-grade ALP elevations showed a trend for increase for subjects exposed to regorafenib. Although the incidence of life-threatening hepatic failure/dysfunction reported with regorafenib \[[@R16]--[@R18]\] was so small that we cannot analyze the pooled data in current study, we believe that careful monitoring of liver function and exclusion of subjects with hepatic impairment may be essential in regorafenib treatment.

Liver is the regulator of chemical homeostasis in the human body and the main site for detoxification of drugs and their metabolites. Accordingly, any potentially toxic metabolite may cause a localized damage. In addition, liver has great capability to regenerative and recovery. However, it is this regenerative capacity that leads to the cytotoxicity from chemotherapy. So liver injury may be an attempting to kill cancerous cells, but generates more problems sometimes when the secondary hepatotoxicity becomes too severe \[[@R36]\]. Interestingly, it has been reported that in most cases hepatic AEs is caused by treatment with multi-kinase inhibitors, especial TKIs \[[@R37]\]. Previous studies have revealed that some TKIs such as imatinib \[[@R38]\] or pazopanib \[[@R39]\] can induce histologic alteration, inflammation, even acute liver failure in cancer patients. Although accumulating preclinical and clinical evidence suggest that TKIs are associated with hepatotoxicity, the underlying mechanism of hepatic AEs remains unclear. Several theories have been proposed during the past two decades. One possible explanation is the generation of reactive metabolites upon metabolism \[[@R40], [@R41]\]. These highly reactive metabolites may be bind to the cysteine groups of proteins such as cytochrome P450 1A1 and 3A4, and thereby affecting cell function and cell death. On the other hand, shah et al. demonstrates that the multiple signal transduction pathways inhibited/activated during oxidative stress play an important role in drug-induced liver injury \[[@R42], [@R43]\]. As for regorafenib, pre-clinical studies suggest that uncoupling of oxidative phosphorylation (OXPHOS) and the resulting mitochondrial permeability transition (MPT) induction and adenosine-triphosphate (ATP) shortage contribute to the hepatocyte injury \[[@R44]\]. Now it is generally believed that various molecular mechanisms are involved in the hepatic AEs, and further studies are needed to reveal the exact reasons underlying regorafenib-associated hepatotoxicity.

TKIs have been shown to cause hepatotoxicity. However, the frequency and severity vary among different agents \[[@R14], [@R15]\]. The discrepancies are partly due to the differences in the mechanisms of action among these agents, the type of underlying malignancies, under reporting, poor follow-up time of exposed patients among trials included in our analysis and other previous studies. Regorafenib has a structure similar to sorafenib differing only in the fluorine on the phenyl ring \[[@R2], [@R45]\]. However, compared with sorafenib, regorafenib appears to have a higher risk of increased AST, ALT, ALP and bilirubin levels (Table [3](#T3){ref-type="table"}). Although the mechanisms underlying this difference have not been completely explained, it cannot rule out that the structural dissimilarity between regorafenib and sorafenib results in the inhibitory effect on UDP-glucuronosyltransferase (UGT) enzymes such as human liver microsomal β-estradiol glucuronidation \[[@R46]\].

###### Relative risk of hepatic toxicities with anti-angiogenic agents

                All-grade: Relative risk (95% CI)   High-grade: Relative risk (95% CI)   References                                                                                                                      
  ------------- ----------------------------------- ------------------------------------ ------------------- --------------------- ------------------- --------------------- --------------------- --------------------- ---------------
  Regorafenib   1.51 (1.13--2.00)                   1.82 (1.25--2.64)                    2.11 (1.01--4.40)   3.10 (2.22--4.34)     1.79 (1.00--3.22)   3.07 (1.30--7.22)     1.06 (0.39--2.90)\*   1.74 (1.09--2.80)     Current study
  Sorafenib     1.43 (1.04--1.97)                   1.53 (1.18--1.99)                    1.41 (1.04--1.91)   1.24 (0.98--1.56)\*   2.25 (1.38--3.67)   1.31 (0.67--2.56)\*   1.27 (0.60--2.72)\*   1.64 (0.89--3.02)\*   \[[@R15]\]

Abbreviations: AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; \**p* \> 0.05.

Although the incidence of fetal hepatic AEs reported with regorafenib is quite limited \[[@R16]--[@R18]\], there are currently no methods to predict subjects at high risk and therefore careful monitoring the function of liver and exclusion of subjects with minor hepatic injury may be essential in subjects treated with regorafenib. Subjects suspected of having drug-induced hepatic impairment should be examined thoroughly of any other hepatic diseases such as biliary obstruction, non-alcoholic fatty liver disease, viral hepatitis, et al. In addition, any potential hepatotoxic medication or agents inhibiting regorafenib should be considered carefully before use. In fact, guidelines have been provided by the manufacturer for the management of hepatic toxicities by some agents, and their adoption may alleviate the risk of hepatic AEs. In regorafenib, FDA recommended that close monitoring with biweekly liver function enzyme measurement for the first two months of therapy should be conducted.

Here, in spite of our stringent exclusion and inclusion criteria, we still managed to gather more than 2,000 patients in current meta-analysis, even though several phase II or III RCTs were excluded. The most common reason for exclusion was due to lack of reporting of liver AEs. The rigorous criterion provided confidence of great quality data and a better comparison, whereby the risk of hepatotoxicity could be regarded with assurance to be associated with regorafenib. However, there were several limitations and challenges in this analysis. First, this was a meta-analysis conducted at the trial level and no clinicopathological variables at the patient level could be analyzed. Second, elevation of bilirubin, AST, ALT and ALP represented hepatic injury but these characteristics did not have good specificity and sensitivity. However, giving the number of life-threatening hepatic failure/dysfunction was quite small, these tests were the only feasible method with available data. Third, the data of hepatic toxicities were not present in many trials, leading to their exclusion from current study. AEs, not like efficacy outcomes, were rarely predetermined for systematic data collection in clinical trials. Accordingly, results of hepatotoxicity highly depended on the investigators, and might be confounded by other clinicopathological characteristics as well, such as presence of liver metastasis. Forth, the pooled incidence of hepatic toxicities had significant heterogeneities, and this maight be due to the different types of underlying malignancies, small sample size among the included trials. Fifth, different versions of Common Terminology Criteria for Adverse Events (CTCAE) criteria were applied for grading. However, classifications of various hepatic AEs were unchanged across these versions.

In conclusion, our meta-analysis revealed that regorafenib was associated with an increased risk of hepatic toxicities. Clinical doctors should be acknowledged of these potential adverse events and hepatotoxicity monitoring at regular intervals should be conducted.

MATERIALS AND METHODS {#s4}
=====================

The present study was conducted in compliance with the recommendations of the *Cochrane Handbook for Systematic Reviews of Interventions* and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R47]\].

Literature search and study selection {#s4_1}
-------------------------------------

A comprehensive systematic search of PubMed and Embase up to June 2017 was carried out without any language restrictions. The only keyword was regorafenib. Both eligibility and exclusion criteria were pre-specified. To be eligible, published trials had to meet the following criteria: (1) patients with solid tumor; (2) patients assigned to treatment with regorafenib at a dose of 160 mg orally once daily during weeks 1--3 of every 4-week cycle; (3) events rates and/or events and sample size available for all-grade and high-grade hepatic toxicities including bilirubin, AST, ALT and ALP. For incidence study, trials that assigned patients to regorafenib monotherapy were used to define the incidence of hepatic AE associated with regorafenib as a single agent. For relative risk study, we included trials that randomly assigned subjects to either control or regorafenib in addition to the same treatment to avoid potential confounding in the risk of hepatic toxicities. Other publications on the topic, including conference abstract, review articles, basic science papers, editorials, early versions of data later published, articles not dealing with regorafenib were not included (Figure [1](#F1){ref-type="fig"}). Since recent studies with regorafenib therapy may be unpublished, electronic searches were also conducted using the major international congresses' proceedings (European Society of Medical Oncology and American Society of Clinical Oncology Annual Meeting). Any discrepancies were settled by discussion and consensus.

Data extraction {#s4_2}
---------------

Identified abstracts were collected and full texts of potentially relevant studies were reviewed for the trial design and reporting of hepatic AEs. The following items were extracted from every study: first author's name, region, year of publication, underlying malignancy, median follow-up, number of patients for analysis, median age, gender, European cooperative oncology group performance status (ECOG PS), median treatment duration, median overall survival, median progression-free survival (Table [1](#T1){ref-type="table"}), events of the following adverse events (both all-grade and high-grade): elevation of bilirubin, AST, ALT and ALP (Table [2](#T2){ref-type="table"}). All the reviewers discussed and resolved any discrepancies in the extracted information.

Statistical analysis {#s4_3}
--------------------

The primary analysis investigated the incidence, relative risk (RR) and corresponding 95% confidence intervals (CIs) of all-grade (Grade 1--4) and high-grade (Grade 3 and 4) hepatic AEs in patients treated with regorafenib. To calculate the incidence, the number of subjects receiving regorafenib alone and the number of subjects with hepatic toxicities (both all-grade and high-grade) were extracted from the eligible single-arm and randomized controlled trials. The proportion of patients with hepatotoxicity and 95% CIs was derived from every study. We calculated both RRs and CIs with data extracted only from randomized controlled trials, comparing the incidence of each adverse event in subjects assigned to regorafenib with subjects assigned to control. Statistical heterogeneity between different trials or subgroups was assessed by Cochrane's Q statistic. The I^2^ statistic was calculated to assess the extent of inconsistency contributable to the heterogeneity across different studies \[[@R48]\]. The assumption of homogeneity was considered invalid for I^2^ \> 25% or *p \<* 0.05. Summary RRs and incidences were calculated using fixed-effects or random-effects models depending on the heterogeneity of included trials. When substantial heterogeneity was not observed, the pooled estimate calculated based on the fixed effects model was reported by using inverse variance method. When substantial heterogeneity was observed, the pooled estimate calculated based on the random-effects model was reported by using the DerSimonian and Laird method, which considers both between-study and within-study variations \[[@R49]\]. Potential publication bias was assessed by visual inspection of a funnel plot, and also evaluated using the tests of Egger et al. \[[@R50]\] and Begg et al. \[[@R51]\]. Two-sided *p \<* 0.05 were considered statistically significant. All analysis was performed using Stata version 12.0 (StataCorp LP, USA).
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